GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provectus Biopharmaceuticals Inc (OTCPK:PVCT) » Definitions » Effective Interest Rate on Debt %

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Effective Interest Rate on Debt % : 7.64% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Provectus Biopharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Provectus Biopharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $0.24 Mil. Provectus Biopharmaceuticals's average total debt for the quarter that ended in Dec. 2023 was $3.09 Mil. Therefore, Provectus Biopharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 7.64%.


Provectus Biopharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for Provectus Biopharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provectus Biopharmaceuticals Effective Interest Rate on Debt % Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.43 7.87 7.53 8.35 8.29

Provectus Biopharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.83 7.46 7.44 8.26 7.64

Competitive Comparison of Provectus Biopharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provectus Biopharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Effective Interest Rate on Debt % falls into.



Provectus Biopharmaceuticals Effective Interest Rate on Debt % Calculation

Provectus Biopharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -0.216/( (2.184+3.026)/ 2 )
=-1  *  -0.216/2.605
=8.29 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.073 + 2.111
=2.184

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.025 + 3.001
=3.026

Provectus Biopharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -0.236/( (3.156+3.026)/ 2 )
=-1  *  -0.236/3.091
=7.64 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.038 + 3.118
=3.156

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.025 + 3.001
=3.026

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Provectus Biopharmaceuticals  (OTCPK:PVCT) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Provectus Biopharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
800 S Gay St, Suite 1610, Knoxville, TN, USA, 37932
Provectus Biopharmaceuticals Inc is a is a clinical-stage biotechnology company. It is engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company has developed and intends to license or market and sell its two prescription drug candidates, PV-10 and PH-10. Its PV-10 is for the treatment of several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The PH-10 is to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.
Executives
Jeffrey Allen Morris 10 percent owner 1729 TRIANGLE PARK DR., MARYVILLE TN 37801
Webster Bailey director 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Heather Raines officer: Chief Financial Officer 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Edward Pershing director 2220 SOUTHERLAND AVE, KNOXVILLE TN 37919
John Iii Lacy director 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
John R Glass officer: See Remarks 7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931
Bruce Horowitz director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Dominic Rodrigues director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Peter R Culpepper officer: Interim CEO, CFO, COO 7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931
Eric Phd Wachter director, officer: Chief Technology Officer PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Jan Koe director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Smith Alfred E. Iv director 191 MAIN STREET, NEW CANAAN CT 06840
Kelly M Mcmasters director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Donald E Adams 10 percent owner 370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401
Timothy Phd Scott director, 10 percent owner, officer: President PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Headlines

From GuruFocus

Provectus Biopharmaceuticals Releases 2023 Stockholder Letter

By Stock market mentor Stock market mentor 01-09-2023